FindTrial
Sign In

Isolated Pelvic and Limb Perfusion in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle

Isolated Pelvic and Limb Perfusion With 1mg TNFa in the Treatment of Locally Advanced Sarcoma of Pelvis and Limbs' Girdle

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00181025
Enrollment
33
Registered
2005-09-16
Start date
2004-05-31
Completion date
Unknown
Last updated
2007-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma of Pelvis

Keywords

Limbs' girdle

Brief summary

This study looks at isolated pelvic perfusion and limbs' girdle with 1 mg tumor necrosis factor alpha (TNFa) in the treatment of locally advanced sarcoma of the pelvis and limbs' girdle.

Interventions

DRUGTasonermine (TNFa)
DRUGMelphalan

Sponsors

Gustave Roussy, Cancer Campus, Grand Paris
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Soft tissue or bone sarcomas locally advanced of the pelvis or limbs' girdle

Exclusion criteria

* Resectable tumor without mutilation

Design outcomes

Primary

MeasureTime frame
Complete response rate on MRI—

Secondary

MeasureTime frame
Histological response—
Objective responses—
Rate of conservative treatments—
Overall survival and disease free survival—
Local and systemic toxicity—

Countries

France

Contacts

Primary ContactSylvie Bonvalot, MD
bonvalot@igr.fr33 1 42 11 363

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026